AD/PD™ 2026 is a leading international conference dedicated to neurodegenerative diseases, convening top medical and scientific experts to present novel findings that advance understanding of disease ...
Poster (1330P): Phase 2 Study of Pembrolizumab (Pemb) plus Plinabulin (Plin) and Docetaxel (Doc) for Patients (pts) with Metastatic NSCLC after Failure on First-line Immune Checkpoint Inhibitor Alone ...
Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA ...
Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -- Oral ...
IDEAYA will also have a poster presentation with data from a second published abstract providing combination mechanism and pre-clinical synergy data between TOP1-payload based ADCs and IDE161, the ...
Title: Results of a Phase 1, Open-label, Dose-escalation Study of Gene Therapy with AAV2-hAQP1 as Treatment for Grade 2 and 3 Radiation-induced Late Xerostomia and Parotid Gland Hypofunction – The ...
-Flamingo is developing two RNA therapies for cancer: danvatirsen, an antisense oligonucleotide in Phase 2 PEMDA-HN study, and FLM-7523, a MALAT1 inhibitor approaching Phase 1- Dr. Andrew Denker, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results